Burning Rock Biotech (BNR) Accounts Payables (2019 - 2026)

Burning Rock Biotech (BNR) has reported Accounts Payables for 8 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 47.17% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 47.17% YoY), while the FY2025 annual figure was $5.8 million, up 26.02% from the prior year.
• Accounts Payables came in at $2.6 million for Q1 2026 at Burning Rock Biotech, down from $5.7 million in the prior quarter.
• The five-year high for Accounts Payables was $15.4 million in Q1 2022, with the low at $2.5 million in Q4 2023.
• Average Accounts Payables over 5 years is $5.4 million, with a median of $4.5 million recorded in 2025.
• Across the five-year window, Accounts Payables surged 102.92% in 2022 and plunged 77.76% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $7.2 million in 2022, then sank by 64.98% to $2.5 million in 2023, then jumped by 87.29% to $4.7 million in 2024, then increased by 22.27% to $5.7 million in 2025, then slumped by 54.46% to $2.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.6 million, $5.7 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.